Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jun 4. doi: 10.1056/NEJMoa1805131. [Epub ahead of print]

2.

Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver.

Vera-Aguilera J, Bedikian AY, Bassett RL, Hwu WJ, Kim KB, Qin Y, Cain S, Washington EW, Davies MA, Patel SM, Homsi J, Papadopoulos NE, Hwu P, Patel SP.

Am J Clin Oncol. 2018 Mar 5. doi: 10.1097/COC.0000000000000436. [Epub ahead of print]

PMID:
29509591
3.

Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma.

Swofford BP, Homsi J.

Case Rep Oncol Med. 2017;2017:8241624. doi: 10.1155/2017/8241624. Epub 2017 Oct 18.

4.

The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.

Puri A, Homsi J.

Melanoma Res. 2017 Oct;27(5):519-523. doi: 10.1097/CMR.0000000000000387.

PMID:
28817445
5.

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.

Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY.

Cancer Immunol Immunother. 2017 Oct;66(10):1359-1366. doi: 10.1007/s00262-017-2030-y. Epub 2017 Jun 13.

PMID:
28612140
6.

Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.

Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P.

J Immunother. 2013 May;36(4):276-86. doi: 10.1097/CJI.0b013e31829419f3.

7.

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P.

Clin Cancer Res. 2012 Dec 15;18(24):6758-70. doi: 10.1158/1078-0432.CCR-12-1177. Epub 2012 Oct 2.

8.

BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.

Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB.

J Cutan Pathol. 2012 Sep;39(9):821-5. doi: 10.1111/j.1600-0560.2012.01950.x. Epub 2012 Jul 19.

9.

Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.

Noor R, Bedikian AY, Mahoney S, Bassett R Jr, Kim K, Papadopoulos N, Hwu WJ, Hwu P, Homsi J.

Support Care Cancer. 2012 Oct;20(10):2583-8. doi: 10.1007/s00520-011-1359-6. Epub 2012 Jan 25.

PMID:
22274951
10.

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.

Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG.

Clin Cancer Res. 2011 Jul 15;17(14):4882-91. doi: 10.1158/1078-0432.CCR-10-2769. Epub 2011 Jun 1.

11.

Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck.

Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB.

Melanoma Res. 2011 Apr;21(2):127-30. doi: 10.1097/CMR.0b013e3283426821.

PMID:
21169870
12.

Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.

Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P.

Am J Clin Oncol. 2011 Dec;34(6):603-10. doi: 10.1097/COC.0b013e3181f9456a.

PMID:
21150567
13.

Immunotherapy of melanoma: an update.

Homsi J, Grimm JC, Hwu P.

Surg Oncol Clin N Am. 2011 Jan;20(1):145-63. doi: 10.1016/j.soc.2010.09.004. Review.

PMID:
21111964
14.

Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P.

Melanoma Res. 2011 Feb;21(1):84-90. doi: 10.1097/CMR.0b013e328341445f. Review.

PMID:
21102360
15.

Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.

Bedikian AY, Silverman JA, Papadopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P.

J Clin Pharmacol. 2011 Aug;51(8):1205-12. doi: 10.1177/0091270010381499. Epub 2010 Oct 26.

PMID:
20978276
16.

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.

Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P.

Melanoma Res. 2010 Dec;20(6):507-10. doi: 10.1097/CMR.0b013e3283403ce9.

PMID:
20881508
17.

Symptom severity and distress in advanced cancer.

Kirkova J, Walsh D, Rybicki L, Davis MP, Aktas A, Tao Jin, Homsi J.

Palliat Med. 2010 Apr;24(3):330-9. doi: 10.1177/0269216309356380. Epub 2009 Dec 16.

PMID:
20015920
18.

A comparative study of 2 sustained-release morphine preparations for pain in advanced cancer.

Homsi J, Walsh D, Lasheen W, Nelson KA, Rybicki LA, Bast J, LeGrand SB.

Am J Hosp Palliat Care. 2010 Mar;27(2):99-105. doi: 10.1177/1049909109345146. Epub 2009 Sep 23.

PMID:
19776372
19.

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.

Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P.

Melanoma Res. 2009 Aug;19(4):238-42. doi: 10.1097/CMR.0b013e32832a1e2f.

PMID:
19521262
20.

Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.

Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P.

Am J Clin Oncol. 2009 Oct;32(5):509-14. doi: 10.1097/COC.0b013e3181942a1f.

PMID:
19506454

Supplemental Content

Loading ...
Support Center